Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by Bureau of Consumer Financial Protection relating to "Arbitration Agreements".
Client: THE INSTITUTE FOR LEGAL REFORM - U.S. CHAMBER OF COMMERCE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
H.R.985 - Fairness in Class Action Litigation and Furthering Asbestos Claim Transparency Act of 2017 H.R. 720/S. 237 - Lawsuit Abuse Reduction Act of 2017 H.R. 1704 ACCESS Act of 2017 (Accessible Care by Curbing Excessive Lawsuits Act of 2017) H.J. Res 111/S.J. Res 47 - disapproval of the CFPB Arbitration Agreements rule
Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by Bureau of Consumer Financial Protection relating to "Arbitration Agreements".
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
LAWYERS FOR CIVIL JUSTICE via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2018 · first_quarter · 1T
Advocating improvements in the civil justice system including class actions, discovery, evidence, jurisdiction, pleadings, and adequate funding for the judiciary
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAXTER HEALTHCARE CORPORATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2017 · third_quarter · 3A
Source: Senate LDA
| CIM GROUP |
| 22 |
| 2013–2015 |
| CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 22 | 2013–2017 |
| NATIONAL CABLE TELECOMMUNICATIONS ASSOCIATION | 19 | 2009–2013 |
| SOUNDEXCHANGE | 19 | 2009–2013 |
| THE INSTITUTE FOR LEGAL REFORM - U.S. CHAMBER OF COMMERCE | 19 | 2008–2017 |
| PRIVATE EQUITY GROWTH CAPITAL COUNCIL (FORMERLY THE PRIVATE EQUITY COUNCIL) | 18 | 2007–2010 |
| Vivus, Inc. | 18 | 2009–2013 |
| COALITION FOR PATIENT SAFETY AND MEDICINE INTEGRITY | 15 | 2011–2013 |
| COALITION TO REFORM THE FOREIGN INVESTMENT IN REAL PROPERTY TAX ACT OF 1980 | 15 | 2009–2012 |
| ABBOTT LABORATORIES | 13 | 2011–2013 |
| QUESTCOR PHARMACEUTICALS | 13 | 2009–2014 |
| SIMON PROPERTY GROUP, INC | 13 | 2011–2014 |
| ARDENT HEALTH SERVICES | 11 | 2013–2014 |
| QUALCOMM INCORPORATED | 11 | 2007–2010 |
| APOLLO MANAGEMENT LP | 10 | 2007–2009 |
| CITADEL INVESTMENT GROUP L L C | 10 | 2007–2009 |
| NEW YORK CITY REGIONAL CENTER | 10 | 2013–2014 |
| PROPERTY CASUALTY INSURERS ASSOCIATION OF AMERICA | 10 | 2012–2014 |
| ANHEUSER-BUSCH COMPANIES, LLC | 9 | 2015–2017 |
| INCO-CHECK INC | 9 | 2007–2009 |
| VERI-TAX COM | 9 | 2007–2009 |
| BIOTECHNOLOGY INDUSTRY ORGANIZATION | 8 | 2015–2016 |
| SYMPLICITY CORPORATION | 8 | 2014–2016 |
| WELSH CARSON ANDERSON & STOWE | 8 | 2007–2009 |
| CITY OF CALABASAS CALIFORNIA | 7 | 2008–2009 |
| WESTERN UNION | 7 | 2009–2010 |
| ZUFFA AND AFFILIATES | 7 | 2008–2010 |
| FAIRFAX FINANCIAL HOLDINGS LIMITED | 6 | 2007–2008 |
| NCM HOLDINGS | 6 | 2009–2010 |
| PFIZER, INC. | 6 | 2015–2016 |
| SANOFI-AVENTIS US | 6 | 2007–2008 |
| UNIVERSITY OF COLORADO | 6 | 2009 |
| 5 | 2007 |
| SAFE RX | 5 | 2016 |
| WMG ACQUISITION CORP. | 5 | 2011–2012 |
| ACE CASH EXPRESS | 4 | 2014–2015 |
| APPLICATION DEVELOPERS ALLIANCE | 4 | 2012–2013 |
| BAXALTA INC. | 4 | 2015–2016 |
| COLORADO REGIONAL CENTER | 4 | 2013 |
| GREYSTONE EB-5 HOLDINGS CORP. | 4 | 2015–2016 |
| HEXION SPECIALTY CHEMICALS, INC. | 4 | 2008 |
| MASIMO CORPORATION | 4 | 2009–2010 |
| PORT INVESTMENT AND DEVELOPMENT INC | 4 | 2008 |
| PORTABLE FUEL CONTAINER MANUFACTURER ASSOCIATION | 4 | 2012 |
| UHLMANN FINANCIAL GROUP | 4 | 2007–2008 |
| WORLD POKER TOUR ENTERPRISES INC | 4 | 2007–2008 |
| ALLIANCE FOR INVESTMENT TRANSPARENCY | 3 | 2007–2008 |
| BIOVAIL CORPORATION | 3 | 2007–2008 |
| BRICKMAN GROUP | 3 | 2007–2008 |
| COALITION FOR MOBILE WIRELESS COMPETITION | 3 | 2011 |
| COALITION FOR PATIENT VISION CARE SAFETY | 3 | 2015 |
| FEDEX CORPORATION | 3 | 2010 |
| MERCK & CO., INC. | 3 | 2009 |
| MOBILE MEDICAL INTERNATIONAL CORPORATION (MMIC) | 3 | 2010 |
| OMNICARE INC | 3 | 2014 |
| PEARL HOTEL INVESTORS, LLC | 3 | 2013 |
| RFXCEL CORP | 3 | 2007 |
| AMERICAN SALVAGE POOL ASSOCIATION | 2 | 2011 |
| ARES MANAGEMENT, FORMERLY REPORTED AS, ARES MANAGEMENT LLC | 2 | 2007 |
| EDUCATION AFFILIATES INC. | 2 | 2010 |
| MEDICAL DEVICE MANUFACTURERS ASSOCIATION | 2 | 2007 |
| NEWSPAPER ASSOCIATION OF AMERICA | 2 | 2008 |
| AMARILLO ECONOMIC DEVELOPMENT CORPORATION | 1 | 2007 |
| CAESARS ENTERPRISE SERVICES LLC | 1 | 2009 |
| FIRST WIND ENERGY, LLC | 1 | 2009 |
| GENWORTH FINANCIAL, INC. | 1 | 2007 |
| ROSS DIXON & BELL LLP | 1 | 2007 |
| SAZERAC COMPANY | 1 | 2011 |
Client: THE INSTITUTE FOR LEGAL REFORM - U.S. CHAMBER OF COMMERCE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
H.R.985 - Fairness in Class Action Litigation and Furthering Asbestos Claim Transparency Act of 2017 H.R. 720/S. 237 - Lawsuit Abuse Reduction Act of 2017 H.R. 1704 ACCESS Act of 2017 (Accessible Care by Curbing Excessive Lawsuits Act of 2017) CFPB arbitration rule H.J. Res 111/S.J. Res 47 - disapproval of the CFPB Arbitration Agreements rule
Affordable and Safe Prescription Drug Importation Act
Client: BAXTER HEALTHCARE CORPORATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Healthcare reform In-home dialysis Telemedicine Availability of medical products H.R. 1245 - Affordable and Safe Prescription Drug Importation Act Implementation of FDA Reauthorization Act of 2017
Affordable and Safe Prescription Drug Importation Act
Client: BAXTER HEALTHCARE CORPORATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Healthcare reform In-home dialysis Telemedicine Availability of medical products H.R. 1245 - Affordable and Safe Prescription Drug Importation Act Implementation of FDA Reauthorization Act of 2017
Affordable and Safe Prescription Drug Importation Act
Client: BAXTER HEALTHCARE CORPORATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Healthcare reform In-home dialysis Telemedicine Availability of medical products H.R. 1245 - Affordable and Safe Prescription Drug Importation Act S. 934/H.R. 2430 - FDA Reauthorization Act of 2017
Affordable and Safe Prescription Drug Importation Act
Client: BAXTER HEALTHCARE CORPORATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Healthcare reform In-home dialysis Telemedicine Availability of medical products H.R. 1245 - Affordable and Safe Prescription Drug Importation Act S. 934/H.R. 2430 - FDA Reauthorization Act of 2017
Affordable and Safe Prescription Drug Importation Act
Client: BAXTER HEALTHCARE CORPORATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Healthcare reform In-home dialysis Telemedicine Availability of medical products H.R. 1245 - Affordable and Safe Prescription Drug Importation Act S. 934/H.R. 2430 - FDA Reauthorization Act of 2017
Affordable and Safe Prescription Drug Importation Act
Client: BAXTER HEALTHCARE CORPORATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Healthcare reform In-home dialysis Availability of medical products H.R. 1245 - Affordable and Safe Prescription Drug Importation Act
DXM Abuse Prevention Act of 2017
Client: CONSUMER HEALTHCARE PRODUCTS ASSOCIATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Dextromethorphan Legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications H.R. 1271 - DXM Abuse Prevention Act of 2017
DXM Abuse Prevention Act of 2017
Client: CONSUMER HEALTHCARE PRODUCTS ASSOCIATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Dextromethorphan Legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications H.R. 1271 - DXM Abuse Prevention Act of 2017
DXM Abuse Prevention Act of 2017
Client: CONSUMER HEALTHCARE PRODUCTS ASSOCIATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Dextromethorphan Legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications H.R. 1271 - DXM Abuse Prevention Act of 2017
DXM Abuse Prevention Act of 2017
Client: CONSUMER HEALTHCARE PRODUCTS ASSOCIATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Dextromethorphan Legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications H.R. 1271 - DXM Abuse Prevention Act of 2017
ACCESS Act of 2017
Client: THE INSTITUTE FOR LEGAL REFORM - U.S. CHAMBER OF COMMERCE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
H.R.985 - Fairness in Class Action Litigation and Furthering Asbestos Claim Transparency Act of 2017 H.R. 720/S. 237 - Lawsuit Abuse Reduction Act of 2017 H.R. 1704 ACCESS Act of 2017 (Accessible Care by Curbing Excessive Lawsuits Act of 2017) H.J. Res 111/S.J. Res 47 - disapproval of the CFPB Arbitration Agreements rule
ACCESS Act of 2017
Client: THE INSTITUTE FOR LEGAL REFORM - U.S. CHAMBER OF COMMERCE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
H.R.985 - Fairness in Class Action Litigation and Furthering Asbestos Claim Transparency Act of 2017 H.R. 720/S. 237 - Lawsuit Abuse Reduction Act of 2017 H.R. 1704 ACCESS Act of 2017 (Accessible Care by Curbing Excessive Lawsuits Act of 2017) CFPB arbitration rule
ACCESS Act of 2017
Client: THE INSTITUTE FOR LEGAL REFORM - U.S. CHAMBER OF COMMERCE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
H.R.985 - Fairness in Class Action Litigation and Furthering Asbestos Claim Transparency Act of 2017 H.R. 720/S. 237 - Lawsuit Abuse Reduction Act of 2017 H.R. 1704 ACCESS Act of 2017 (Accessible Care by Curbing Excessive Lawsuits Act of 2017) CFPB arbitration rule H.J. Res 111/S.J. Res 47 - disapproval of the CFPB Arbitration Agreements rule
FDA Reauthorization Act of 2017
Client: BAXTER HEALTHCARE CORPORATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Healthcare reform In-home dialysis Telemedicine Availability of medical products H.R. 1245 - Affordable and Safe Prescription Drug Importation Act S. 934/H.R. 2430 - FDA Reauthorization Act of 2017
FDA Reauthorization Act of 2017
Client: BAXTER HEALTHCARE CORPORATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Healthcare reform In-home dialysis Telemedicine Availability of medical products H.R. 1245 - Affordable and Safe Prescription Drug Importation Act S. 934/H.R. 2430 - FDA Reauthorization Act of 2017
FDA Reauthorization Act of 2017
Client: BAXTER HEALTHCARE CORPORATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Healthcare reform In-home dialysis Telemedicine Availability of medical products H.R. 1245 - Affordable and Safe Prescription Drug Importation Act S. 934/H.R. 2430 - FDA Reauthorization Act of 2017
Restoring Access to Medication Act of 2017
Client: CONSUMER HEALTHCARE PRODUCTS ASSOCIATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to utilization of HSA and FSA H.R. 394/S. 85 - Restoring Access to Medication Act
Restoring Access to Medication Act of 2017
Client: CONSUMER HEALTHCARE PRODUCTS ASSOCIATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to utilization of HSA and FSA H.R. 394/S. 85 - Restoring Access to Medication Act
Restoring Access to Medication Act of 2017
Client: CONSUMER HEALTHCARE PRODUCTS ASSOCIATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to utilization of HSA and FSA H.R. 394/S. 85 - Restoring Access to Medication Act
Restoring Access to Medication Act of 2017
Client: CONSUMER HEALTHCARE PRODUCTS ASSOCIATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to utilization of HSA and FSA H.R. 394/S. 85 - Restoring Access to Medication Act
Lawsuit Abuse Reduction Act of 2017
Client: THE INSTITUTE FOR LEGAL REFORM - U.S. CHAMBER OF COMMERCE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
H.R.985 - Fairness in Class Action Litigation and Furthering Asbestos Claim Transparency Act of 2017 H.R. 720/S. 237 - Lawsuit Abuse Reduction Act of 2017 H.R. 1704 ACCESS Act of 2017 (Accessible Care by Curbing Excessive Lawsuits Act of 2017) CFPB arbitration rule H.J. Res 111/S.J. Res 47 - disapproval of the CFPB Arbitration Agreements rule
Lawsuit Abuse Reduction Act of 2017
Client: THE INSTITUTE FOR LEGAL REFORM - U.S. CHAMBER OF COMMERCE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
H.R.985 - Fairness in Class Action Litigation and Furthering Asbestos Claim Transparency Act of 2017 H.R. 720/S. 237 - Lawsuit Abuse Reduction Act of 2017 H.R. 1704 ACCESS Act of 2017 (Accessible Care by Curbing Excessive Lawsuits Act of 2017) H.J. Res 111/S.J. Res 47 - disapproval of the CFPB Arbitration Agreements rule
Lawsuit Abuse Reduction Act of 2017
Client: THE INSTITUTE FOR LEGAL REFORM - U.S. CHAMBER OF COMMERCE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
H.R.985 - Fairness in Class Action Litigation and Furthering Asbestos Claim Transparency Act of 2017 H.R. 720/S. 237 - Lawsuit Abuse Reduction Act of 2017 H.R. 1704 ACCESS Act of 2017 (Accessible Care by Curbing Excessive Lawsuits Act of 2017) CFPB arbitration rule
Fairness in Class Action Litigation and Furthering Asbestos Claim Transparency Act of 2017
Client: THE INSTITUTE FOR LEGAL REFORM - U.S. CHAMBER OF COMMERCE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
H.R.985 - Fairness in Class Action Litigation and Furthering Asbestos Claim Transparency Act of 2017 H.R. 720/S. 237 - Lawsuit Abuse Reduction Act of 2017 H.R. 1704 ACCESS Act of 2017 (Accessible Care by Curbing Excessive Lawsuits Act of 2017) CFPB arbitration rule H.J. Res 111/S.J. Res 47 - disapproval of the CFPB Arbitration Agreements rule
Fairness in Class Action Litigation and Furthering Asbestos Claim Transparency Act of 2017
Client: THE INSTITUTE FOR LEGAL REFORM - U.S. CHAMBER OF COMMERCE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
H.R.985 - Fairness in Class Action Litigation and Furthering Asbestos Claim Transparency Act of 2017 H.R. 720/S. 237 - Lawsuit Abuse Reduction Act of 2017 H.R. 1704 ACCESS Act of 2017 (Accessible Care by Curbing Excessive Lawsuits Act of 2017) CFPB arbitration rule
Fairness in Class Action Litigation and Furthering Asbestos Claim Transparency Act of 2017
Client: THE INSTITUTE FOR LEGAL REFORM - U.S. CHAMBER OF COMMERCE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
H.R.985 - Fairness in Class Action Litigation and Furthering Asbestos Claim Transparency Act of 2017 H.R. 720/S. 237 - Lawsuit Abuse Reduction Act of 2017 H.R. 1704 ACCESS Act of 2017 (Accessible Care by Curbing Excessive Lawsuits Act of 2017) H.J. Res 111/S.J. Res 47 - disapproval of the CFPB Arbitration Agreements rule
Lawsuit Abuse Reduction Act of 2017
Client: THE INSTITUTE FOR LEGAL REFORM - U.S. CHAMBER OF COMMERCE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
H.R.985 - Fairness in Class Action Litigation and Furthering Asbestos Claim Transparency Act of 2017 H.R. 720/S. 237 - Lawsuit Abuse Reduction Act of 2017 H.R. 1704 ACCESS Act of 2017 (Accessible Care by Curbing Excessive Lawsuits Act of 2017) H.J. Res 111/S.J. Res 47 - disapproval of the CFPB Arbitration Agreements rule
Lawsuit Abuse Reduction Act of 2017
Client: THE INSTITUTE FOR LEGAL REFORM - U.S. CHAMBER OF COMMERCE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
H.R.985 - Fairness in Class Action Litigation and Furthering Asbestos Claim Transparency Act of 2017 H.R. 720/S. 237 - Lawsuit Abuse Reduction Act of 2017 H.R. 1704 ACCESS Act of 2017 (Accessible Care by Curbing Excessive Lawsuits Act of 2017) CFPB arbitration rule
Lawsuit Abuse Reduction Act of 2017
Client: THE INSTITUTE FOR LEGAL REFORM - U.S. CHAMBER OF COMMERCE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
H.R.985 - Fairness in Class Action Litigation and Furthering Asbestos Claim Transparency Act of 2017 H.R. 720/S. 237 - Lawsuit Abuse Reduction Act of 2017 H.R. 1704 ACCESS Act of 2017 (Accessible Care by Curbing Excessive Lawsuits Act of 2017) CFPB arbitration rule H.J. Res 111/S.J. Res 47 - disapproval of the CFPB Arbitration Agreements rule
Restoring Access to Medication Act of 2017
Client: CONSUMER HEALTHCARE PRODUCTS ASSOCIATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to utilization of HSA and FSA H.R. 394/S. 85 - Restoring Access to Medication Act
Restoring Access to Medication Act of 2017
Client: CONSUMER HEALTHCARE PRODUCTS ASSOCIATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to utilization of HSA and FSA H.R. 394/S. 85 - Restoring Access to Medication Act
Restoring Access to Medication Act of 2017
Client: CONSUMER HEALTHCARE PRODUCTS ASSOCIATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to utilization of HSA and FSA H.R. 394/S. 85 - Restoring Access to Medication Act
Restoring Access to Medication Act of 2017
Client: CONSUMER HEALTHCARE PRODUCTS ASSOCIATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to utilization of HSA and FSA H.R. 394/S. 85 - Restoring Access to Medication Act
FDA Reauthorization Act of 2017
Client: BAXTER HEALTHCARE CORPORATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Healthcare reform In-home dialysis Telemedicine Availability of medical products H.R. 1245 - Affordable and Safe Prescription Drug Importation Act S. 934/H.R. 2430 - FDA Reauthorization Act of 2017
FDA Reauthorization Act of 2017
Client: BAXTER HEALTHCARE CORPORATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Healthcare reform In-home dialysis Telemedicine Availability of medical products H.R. 1245 - Affordable and Safe Prescription Drug Importation Act S. 934/H.R. 2430 - FDA Reauthorization Act of 2017
FDA Reauthorization Act of 2017
Client: BAXTER HEALTHCARE CORPORATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Healthcare reform In-home dialysis Telemedicine Availability of medical products H.R. 1245 - Affordable and Safe Prescription Drug Importation Act S. 934/H.R. 2430 - FDA Reauthorization Act of 2017
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by Bureau of Consumer Financial Protection relating to "Arbitration Agreements".
Client: THE INSTITUTE FOR LEGAL REFORM - U.S. CHAMBER OF COMMERCE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
H.R.985 - Fairness in Class Action Litigation and Furthering Asbestos Claim Transparency Act of 2017 H.R. 720/S. 237 - Lawsuit Abuse Reduction Act of 2017 H.R. 1704 ACCESS Act of 2017 (Accessible Care by Curbing Excessive Lawsuits Act of 2017) H.J. Res 111/S.J. Res 47 - disapproval of the CFPB Arbitration Agreements rule
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by Bureau of Consumer Financial Protection relating to "Arbitration Agreements".
Client: THE INSTITUTE FOR LEGAL REFORM - U.S. CHAMBER OF COMMERCE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
H.R.985 - Fairness in Class Action Litigation and Furthering Asbestos Claim Transparency Act of 2017 H.R. 720/S. 237 - Lawsuit Abuse Reduction Act of 2017 H.R. 1704 ACCESS Act of 2017 (Accessible Care by Curbing Excessive Lawsuits Act of 2017) CFPB arbitration rule H.J. Res 111/S.J. Res 47 - disapproval of the CFPB Arbitration Agreements rule
Chronic Kidney Disease Improvement in Research and Treatment Act of 2015
Client: BAXTER HEALTHCARE CORPORATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Healthcare reform In-home dialysis H.R. 1130/S.598 - The Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 FDA Reform Availability of medical products
Chronic Kidney Disease Improvement in Research and Treatment Act of 2015
Client: BAXTER HEALTHCARE CORPORATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Healthcare reform In-home dialysis H.R. 1130/S.598 - The Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 FDA Reform - 21st Century Cures Act Availability of medical products
Chronic Kidney Disease Improvement in Research and Treatment Act of 2015
Client: BAXTER HEALTHCARE CORPORATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Healthcare reform In-home dialysis H.R. 1130/S.598 - The Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 FDA Reform Availability of medical products
Chronic Kidney Disease Improvement in Research and Treatment Act of 2015
Client: BAXTER HEALTHCARE CORPORATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Healthcare reform In-home dialysis H.R. 1130/S.598 - The Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 FDA Reform Availability of medical products
Restoring Access to Medication and Improving Health Savings Act of 2016
Client: CONSUMER HEALTHCARE PRODUCTS ASSOCIATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
S.709 - Restoring Access to Medication Act H.R.1270 - Restoring Access to Medication Act
Restoring Access to Medication and Improving Health Savings Act of 2016
Client: CONSUMER HEALTHCARE PRODUCTS ASSOCIATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
S.709 - Restoring Access to Medication Act H.R.1270 - Restoring Access to Medication Act
Restoring Access to Medication and Improving Health Savings Act of 2016
Client: CONSUMER HEALTHCARE PRODUCTS ASSOCIATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
S.709 - Restoring Access to Medication Act H.R.1270 - Restoring Access to Medication Act
Restoring Access to Medication and Improving Health Savings Act of 2016
Client: CONSUMER HEALTHCARE PRODUCTS ASSOCIATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
S.709 - Restoring Access to Medication Act H.R.1270 - Restoring Access to Medication Act
National Defense Authorization Act for Fiscal Year 2017
Client: SAFE RX · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Educating policy makers about anti-pilfering technology known as locking prescription vials (LPVs) Issues relating to establishing a pilot program for LPVs Issues relating to DEA's authority to regulate dispensing Schedule II-IV drugs S. 524/H.R. 953 (PL 114-328) Comprehensive Addiction and Recovery Act of 2016 - Title VII, Section 746 Department of Defense Study on preventing the diversion of opiod medications S. 2943/H.R. 4909 (PL 114-198) National Defense Authorization Act for fiscal year 2017 - Title III, Section 301 Evidence based prescription opiod and heroin treatment and interventions demonstration
National Defense Authorization Act for Fiscal Year 2017
Client: SAFE RX · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Educating policy makers about anti-pilfering technology known as locking prescription vials (LPVs) Issues relating to establishing a pilot program for LPVs Issues relating to DEA's authority to regulate dispensing Schedule II-IV drugs S. 524/H.R. 953 - Comprehensive Addiction and Recovery Act of 2016 S. 2943/H.R. 4909 - National Defense Authorization Act for fiscal year 2017
National Defense Authorization Act for Fiscal Year 2017
Client: SAFE RX · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Educating policy makers about anti-pilfering technology known as locking prescription vials (LPVs) Issues relating to establishing a pilot program for LPVs Issues relating to DEA's authority to regulate dispensing Schedule II-IV drugs S. 524/H.R. 953 - Comprehensive Addiction and Recovery Act of 2016 S. 2943/H.R. 4909 - National Defense Authorization Act for fiscal year 2017
Helping Hospitals Improve Patient Care Act of 2016
Client: UNIVERSITY OF UTAH · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Utah genome project Healthcare delivery innovation Telemedicine Precision medicine Cancer research S. 2873/H.R. 5395 - Expanding Capacity for Health Outcomes Act Zika Research S. 2873 & H.R. 5395 - The ECHO Act H.R. 5273 - Helping Hospitals Improve Patient Care Act of 2016
Helping Hospitals Improve Patient Care Act of 2016
Client: UNIVERSITY OF UTAH · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Graduate medical education Issues related to provider reimbursement H.R. 5273 - Helping Hospitals Improve Patient Care Act of 2016
Helping Hospitals Improve Patient Care Act of 2016
Client: UNIVERSITY OF UTAH · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Graduate medical education Issues related to provider reimbursement H.R. 5273 - Helping Hospitals Improve Patient Care Act of 2016
Helping Hospitals Improve Patient Care Act of 2016
Client: UNIVERSITY OF UTAH · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Utah genome project Healthcare delivery innovation Telemedicine Precision medicine Cancer research S. 2873/H.R. 5395 - Expanding Capacity for Health Outcomes Act Zika Research S. 2873 & H.R. 5395 - The ECHO Act H.R. 5273 - Helping Hospitals Improve Patient Care Act of 2016
Helping Hospitals Improve Patient Care Act of 2016
Client: UNIVERSITY OF UTAH · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Graduate medical education Issues related to provider reimbursement H.R. 5273 - Helping Hospitals Improve Patient Care Act of 2016
Helping Hospitals Improve Patient Care Act of 2016
Client: UNIVERSITY OF UTAH · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Utah genome project Healthcare delivery innovation Telemedicine Precision medicine Cancer research S. 2873/H.R. 5395 - Expanding Capacity for Health Outcomes Act H.R. 5273 - Helping Hospitals Improve Patient Care Act of 2016
Helping Hospitals Improve Patient Care Act of 2016
Client: UNIVERSITY OF UTAH · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Graduate medical education Issues related to provider reimbursement H.R. 5273 - Helping Hospitals Improve Patient Care Act of 2016
Expanding Capacity for Health Outcomes Act
Client: UNIVERSITY OF UTAH · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Utah genome project Healthcare delivery innovation Telemedicine Precision medicine Cancer research S. 2873/H.R. 5395 - Expanding Capacity for Health Outcomes Act H.R. 5273 - Helping Hospitals Improve Patient Care Act of 2016
Expanding Capacity for Health Outcomes Act
Client: UNIVERSITY OF UTAH · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Utah genome project Healthcare delivery innovation Telemedicine Precision medicine Cancer research S. 2873/H.R. 5395 - Expanding Capacity for Health Outcomes Act
Expanding Capacity for Health Outcomes Act
Client: UNIVERSITY OF UTAH · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Utah genome project Healthcare delivery innovation Telemedicine Precision medicine Cancer research S. 2873/H.R. 5395 - Expanding Capacity for Health Outcomes Act Zika Research S. 2873 & H.R. 5395 - The ECHO Act H.R. 5273 - Helping Hospitals Improve Patient Care Act of 2016
Expanding Capacity for Health Outcomes Act
Client: UNIVERSITY OF UTAH · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Utah genome project Healthcare delivery innovation Telemedicine Precision medicine Cancer research S. 2873/H.R. 5395 - Expanding Capacity for Health Outcomes Act Zika Research S. 2873 & H.R. 5395 - The ECHO Act H.R. 5273 - Helping Hospitals Improve Patient Care Act of 2016
Innovation Act
Client: JOHNSON & JOHNSON SERVICES, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
H.R. 9 - Innovation Act S. 632 - STRONG Patents Act of 2015
Innovation Act
Client: BIOTECHNOLOGY INDUSTRY ORGANIZATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
H.R.9 - Innovation Act S.1137 - PATENT Act
Innovation Act
Client: JOHNSON & JOHNSON SERVICES, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
H.R. 9 - Innovation Act S. 632 - STRONG Patents Act of 2015
Innovation Act
Client: JOHNSON & JOHNSON SERVICES, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
H.R. 9 - Innovation Act S. 632 - STRONG Patents Act of 2015
Innovation Act
Client: BIOTECHNOLOGY INDUSTRY ORGANIZATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
H.R.9 - Innovation Act S.1137 - PATENT Act
Innovation Act
Client: JOHNSON & JOHNSON SERVICES, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
H.R. 9 - Innovation Act S. 632 - STRONG Patents Act of 2015
Comprehensive Addiction and Recovery Act of 2015
Client: JOHNSON & JOHNSON SERVICES, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to contact lens pricing Issues related to pseudoephedrine Issues related to the regulation of cosmetic products Safe use of OTC products S. 524 Comprehensive Addiction and Recovery Act of 2016 H.R. 953 Comprehensive Addiction and Recovery Act of 2015
Comprehensive Addiction and Recovery Act of 2015
Client: JOHNSON & JOHNSON SERVICES, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to contact lens pricing Issues related to pseudoephedrine Issues related to the regulation of cosmetic products Safe use of OTC products S. 524 Comprehensive Addiction and Recovery Act of 2016 H.R. 953 Comprehensive Addiction and Recovery Act of 2015
Comprehensive Addiction and Recovery Act of 2015
Client: SAFE RX · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Educating policy makers about anti-pilfering technology known as locking prescription vials (LPVs) Issues relating to establishing a pilot program for LPVs Issues relating to DEA's authority to regulate dispensing Schedule II-IV drugs S. 524/H.R. 953 (PL 114-328) Comprehensive Addiction and Recovery Act of 2016 - Title VII, Section 746 Department of Defense Study on preventing the diversion of opiod medications S. 2943/H.R. 4909 (PL 114-198) National Defense Authorization Act for fiscal year 2017 - Title III, Section 301 Evidence based prescription opiod and heroin treatment and interventions demonstration
Comprehensive Addiction and Recovery Act of 2015
Client: JOHNSON & JOHNSON SERVICES, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to contact lens pricing Issues related to pseudoephedrine Issues related to the regulation of cosmetic products Safe use of OTC products S. 524 Comprehensive Addiction and Recovery Act of 2016 H.R. 953 Comprehensive Addiction and Recovery Act of 2015
Comprehensive Addiction and Recovery Act of 2015
Client: SAFE RX · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Educating policy makers about anti-pilfering technology known as locking prescription vials (LPVs) Issues relating to establishing a pilot program for LPVs Issues relating to DEA's authority to regulate dispensing Schedule II-IV drugs S. 524/H.R. 953 - Comprehensive Addiction and Recovery Act of 2016 S. 2943/H.R. 4909 - National Defense Authorization Act for fiscal year 2017
Comprehensive Addiction and Recovery Act of 2015
Client: JOHNSON & JOHNSON SERVICES, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to contact lens pricing Issues related to pseudoephedrine Issues related to the regulation of cosmetic products Safe use of OTC products S. 524 Comprehensive Addiction and Recovery Act of 2016 H.R. 953 Comprehensive Addiction and Recovery Act of 2015
Comprehensive Addiction and Recovery Act of 2015
Client: SAFE RX · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Educating policy makers about anti-pilfering technology known as locking prescription vials (LPVs) Issues relating to establishing a pilot program for LPVs Issues relating to DEA's authority to regulate dispensing Schedule II-IV drugs S. 524/H.R. 953 - Comprehensive Addiction and Recovery Act of 2016 S. 2943/H.R. 4909 - National Defense Authorization Act for fiscal year 2017
PATENT Act
Client: BIOTECHNOLOGY INDUSTRY ORGANIZATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
H.R.9 - Innovation Act S.1137 - PATENT Act
PATENT Act
Client: BIOTECHNOLOGY INDUSTRY ORGANIZATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
H.R.9 - Innovation Act S.1137 - PATENT Act
American Job Creation and Investment Promotion Reform Act of 2015
Client: GREYSTONE EB-5 HOLDINGS CORP. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
EB-5 and related matters S.1501-American Job Creation and Investment Promotion Reform Act of 2015
Expanding Capacity for Health Outcomes Act
Client: UNIVERSITY OF UTAH · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Utah genome project Healthcare delivery innovation Telemedicine Precision medicine Cancer research S. 2873/H.R. 5395 - Expanding Capacity for Health Outcomes Act Zika Research S. 2873 & H.R. 5395 - The ECHO Act H.R. 5273 - Helping Hospitals Improve Patient Care Act of 2016
Expanding Capacity for Health Outcomes Act
Client: UNIVERSITY OF UTAH · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Utah genome project Healthcare delivery innovation Telemedicine Precision medicine Cancer research S. 2873/H.R. 5395 - Expanding Capacity for Health Outcomes Act H.R. 5273 - Helping Hospitals Improve Patient Care Act of 2016
Expanding Capacity for Health Outcomes Act
Client: UNIVERSITY OF UTAH · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Utah genome project Healthcare delivery innovation Telemedicine Precision medicine Cancer research S. 2873/H.R. 5395 - Expanding Capacity for Health Outcomes Act Zika Research S. 2873 & H.R. 5395 - The ECHO Act H.R. 5273 - Helping Hospitals Improve Patient Care Act of 2016
Expanding Capacity for Health Outcomes Act
Client: UNIVERSITY OF UTAH · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Utah genome project Healthcare delivery innovation Telemedicine Precision medicine Cancer research S. 2873/H.R. 5395 - Expanding Capacity for Health Outcomes Act
National Defense Authorization Act for Fiscal Year 2017
Client: SAFE RX · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Educating policy makers about anti-pilfering technology known as locking prescription vials (LPVs) Issues relating to establishing a pilot program for LPVs Issues relating to DEA's authority to regulate dispensing Schedule II-IV drugs S. 524/H.R. 953 - Comprehensive Addiction and Recovery Act of 2016 S. 2943/H.R. 4909 - National Defense Authorization Act for fiscal year 2017
National Defense Authorization Act for Fiscal Year 2017
Client: SAFE RX · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Educating policy makers about anti-pilfering technology known as locking prescription vials (LPVs) Issues relating to establishing a pilot program for LPVs Issues relating to DEA's authority to regulate dispensing Schedule II-IV drugs S. 524/H.R. 953 (PL 114-328) Comprehensive Addiction and Recovery Act of 2016 - Title VII, Section 746 Department of Defense Study on preventing the diversion of opiod medications S. 2943/H.R. 4909 (PL 114-198) National Defense Authorization Act for fiscal year 2017 - Title III, Section 301 Evidence based prescription opiod and heroin treatment and interventions demonstration
National Defense Authorization Act for Fiscal Year 2017
Client: SAFE RX · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Educating policy makers about anti-pilfering technology known as locking prescription vials (LPVs) Issues relating to establishing a pilot program for LPVs Issues relating to DEA's authority to regulate dispensing Schedule II-IV drugs S. 524/H.R. 953 - Comprehensive Addiction and Recovery Act of 2016 S. 2943/H.R. 4909 - National Defense Authorization Act for fiscal year 2017
Comprehensive Addiction and Recovery Act of 2016
Client: JOHNSON & JOHNSON SERVICES, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to contact lens pricing Issues related to pseudoephedrine Issues related to the regulation of cosmetic products Safe use of OTC products S. 524 Comprehensive Addiction and Recovery Act of 2016 H.R. 953 Comprehensive Addiction and Recovery Act of 2015
Comprehensive Addiction and Recovery Act of 2016
Client: SAFE RX · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Educating policy makers about anti-pilfering technology known as locking prescription vials (LPVs) Issues relating to establishing a pilot program for LPVs Issues relating to DEA's authority to regulate dispensing Schedule II-IV drugs S. 524/H.R. 953 - Comprehensive Addiction and Recovery Act of 2016 S. 2943/H.R. 4909 - National Defense Authorization Act for fiscal year 2017
Comprehensive Addiction and Recovery Act of 2016
Client: CONSUMER HEALTHCARE PRODUCTS ASSOCIATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Preserving consumer access to over-the-counter medicines containing pseudoephedrine Rx-to-OTC switch Issues related to monograph reform S. 524 - Comprehensive Addiction and Recovery Act of 2016
Comprehensive Addiction and Recovery Act of 2016
Client: SAFE RX · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Educating policy makers about anti-pilfering technology known as locking prescription vials (LPVs) Issues relating to establishing a pilot program for LPVs Issues relating to DEA's authority to regulate dispensing Schedule II-IV drugs S. 524/H.R. 953 (PL 114-328) Comprehensive Addiction and Recovery Act of 2016 - Title VII, Section 746 Department of Defense Study on preventing the diversion of opiod medications S. 2943/H.R. 4909 (PL 114-198) National Defense Authorization Act for fiscal year 2017 - Title III, Section 301 Evidence based prescription opiod and heroin treatment and interventions demonstration
Comprehensive Addiction and Recovery Act of 2016
Client: JOHNSON & JOHNSON SERVICES, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to contact lens pricing Issues related to pseudoephedrine Issues related to the regulation of cosmetic products Safe use of OTC products S. 524 Comprehensive Addiction and Recovery Act of 2016 H.R. 953 Comprehensive Addiction and Recovery Act of 2015
Comprehensive Addiction and Recovery Act of 2016
Client: JOHNSON & JOHNSON SERVICES, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to contact lens pricing Issues related to pseudoephedrine Issues related to the regulation of cosmetic products Safe use of OTC products S. 524 Comprehensive Addiction and Recovery Act of 2016 H.R. 953 Comprehensive Addiction and Recovery Act of 2015
Comprehensive Addiction and Recovery Act of 2016
Client: SAFE RX · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Educating policy makers about anti-pilfering technology known as locking prescription vials (LPVs) Issues relating to establishing a pilot program for LPVs Issues relating to DEA's authority to regulate dispensing Schedule II-IV drugs S. 524/H.R. 953 - Comprehensive Addiction and Recovery Act of 2016 S. 2943/H.R. 4909 - National Defense Authorization Act for fiscal year 2017
Comprehensive Addiction and Recovery Act of 2016
Client: CONSUMER HEALTHCARE PRODUCTS ASSOCIATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Preserving consumer access to over-the-counter medicines containing pseudoephedrine Rx-to-OTC switch Issues related to monograph reform S. 524 - Comprehensive Addiction and Recovery Act of 2016
Comprehensive Addiction and Recovery Act of 2016
Client: CONSUMER HEALTHCARE PRODUCTS ASSOCIATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Preserving consumer access to over-the-counter medicines containing pseudoephedrine Rx-to-OTC switch Issues related to monograph reform The Microbead-Free Waters Act of 2015 S. 524 - Comprehensive Addiction and Recovery Act of 2016
Comprehensive Addiction and Recovery Act of 2016
Client: JOHNSON & JOHNSON SERVICES, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to contact lens pricing Issues related to pseudoephedrine Issues related to the regulation of cosmetic products Safe use of OTC products S. 524 Comprehensive Addiction and Recovery Act of 2016 H.R. 953 Comprehensive Addiction and Recovery Act of 2015
Chronic Kidney Disease Improvement in Research and Treatment Act of 2015
Client: BAXTER HEALTHCARE CORPORATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Healthcare reform In-home dialysis H.R. 1130/S.598 - The Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 FDA Reform Availability of medical products
Chronic Kidney Disease Improvement in Research and Treatment Act of 2015
Client: BAXTER HEALTHCARE CORPORATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Healthcare reform In-home dialysis H.R. 1130/S.598 - The Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 FDA Reform Availability of medical products
Chronic Kidney Disease Improvement in Research and Treatment Act of 2015
Client: BAXTER HEALTHCARE CORPORATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Healthcare reform In-home dialysis H.R. 1130/S.598 - The Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 FDA Reform - 21st Century Cures Act Availability of medical products
Chronic Kidney Disease Improvement in Research and Treatment Act of 2015
Client: BAXTER HEALTHCARE CORPORATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Healthcare reform In-home dialysis H.R. 1130/S.598 - The Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 FDA Reform Availability of medical products
STRONG Patents Act of 2015
Client: JOHNSON & JOHNSON SERVICES, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
H.R. 9 - Innovation Act S. 632 - STRONG Patents Act of 2015
Corporate tax issues, including deferral and device tax Tax reform Issues related to the border adjustment tax
Healthcare reform In-home dialysis Telemedicine Availability of medical products H.R. 1245 - Affordable and Safe Prescription Drug Importation Act S. 934/H.R. 2430 - FDA Reauthorization Act of 2017
Funding issues for Medicare Part B 340 B drug discount program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2017 · fourth_quarter · 4A
Issues related to pseudoephedrine Issues related to the regulation of cosmetic products Safe use of OTC products Matters related to American Medical Association Resolution 208(A-16) adopted April 2016
Issues related to 340B drug discount program Issues related to FDA user fees and ACA repeal/replace
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAXTER HEALTHCARE CORPORATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2017 · fourth_quarter · 4A
Healthcare reform In-home dialysis Telemedicine Availability of medical products H.R. 1245 - Affordable and Safe Prescription Drug Importation Act Implementation of FDA Reauthorization Act of 2017
Funding issues for Medicare Part B 340 B drug discount program
Corporate tax issues, including deferral and device tax Issues related to the border adjustment tax Issues related to Puerto Rico
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2017 · fourth_quarter · 4A
Issues related to pseudoephedrine Issues related to the regulation of cosmetic products Safe use of OTC products Matters related to American Medical Association Resolution 208(A-16) adopted April 2016
Issues related to 340B drug discount program Issues related to FDA user fees and ACA repeal/replace
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
JOHNSON & JOHNSON SERVICES, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2017 · fourth_quarter · Q4
Issues related to 340B drug discount program Issues related to FDA user fees and ACA repeal/replace
Issues related to pseudoephedrine Issues related to the regulation of cosmetic products Safe use of OTC products Matters related to American Medical Association Resolution 208(A-16) adopted April 2016
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE INSTITUTE FOR LEGAL REFORM - U.S. CHAMBER OF COMMERCE via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2017 · fourth_quarter · Q4
H.R.985 - Fairness in Class Action Litigation and Furthering Asbestos Claim Transparency Act of 2017 H.R. 720/S. 237 - Lawsuit Abuse Reduction Act of 2017 H.R. 1704 ACCESS Act of 2017 (Accessible Care by Curbing Excessive Lawsuits Act of 2017) H.J. Res 111/S.J. Res 47 - disapproval of the CFPB Arbitration Agreements rule
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LAWYERS FOR CIVIL JUSTICE via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2017 · fourth_quarter · Q4
Advocating improvements in the civil justice system including class actions, discovery, evidence, jurisdiction, pleadings, and adequate funding for the judiciary
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONSUMER HEALTHCARE PRODUCTS ASSOCIATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2017 · fourth_quarter · 4T
Preserving consumer access to over-the-counter medicines containing pseudoephedrine Rx-to-OTC switch Issues related to monograph reform
Dextromethorphan Legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications H.R. 1271 - DXM Abuse Prevention Act of 2017
Issues related to utilization of HSA and FSA H.R. 394/S. 85 - Restoring Access to Medication Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAXTER HEALTHCARE CORPORATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2017 · fourth_quarter · Q4
Corporate tax issues, including deferral and device tax Issues related to the border adjustment tax Issues related to Puerto Rico
Funding issues for Medicare Part B 340 B drug discount program
Healthcare reform In-home dialysis Telemedicine Availability of medical products H.R. 1245 - Affordable and Safe Prescription Drug Importation Act Implementation of FDA Reauthorization Act of 2017
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ANHEUSER-BUSCH COMPANIES, LLC via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2017 · fourth_quarter · Q4
Issues related to competition policy
THE INSTITUTE FOR LEGAL REFORM - U.S. CHAMBER OF COMMERCE via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2017 · third_quarter · Q3
H.R.985 - Fairness in Class Action Litigation and Furthering Asbestos Claim Transparency Act of 2017 H.R. 720/S. 237 - Lawsuit Abuse Reduction Act of 2017 H.R. 1704 ACCESS Act of 2017 (Accessible Care by Curbing Excessive Lawsuits Act of 2017) CFPB arbitration rule H.J. Res 111/S.J. Res 47 - disapproval of the CFPB Arbitration Agreements rule
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LAWYERS FOR CIVIL JUSTICE via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2017 · third_quarter · Q3
Advocating improvements in the civil justice system including class actions, discovery, evidence, jurisdiction, pleadings, and adequate funding for the judiciary
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAXTER HEALTHCARE CORPORATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2017 · third_quarter · Q3
Funding issues for Medicare Part B 340 B drug discount program
Healthcare reform In-home dialysis Telemedicine Availability of medical products H.R. 1245 - Affordable and Safe Prescription Drug Importation Act S. 934/H.R. 2430 - FDA Reauthorization Act of 2017
Corporate tax issues, including deferral and device tax Tax reform Issues related to the border adjustment tax
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONSUMER HEALTHCARE PRODUCTS ASSOCIATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2017 · third_quarter · Q3
Issues related to utilization of HSA and FSA H.R. 394/S. 85 - Restoring Access to Medication Act
Dextromethorphan Legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications H.R. 1271 - DXM Abuse Prevention Act of 2017
Preserving consumer access to over-the-counter medicines containing pseudoephedrine Rx-to-OTC switch Issues related to monograph reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2017 · third_quarter · Q3
Issues related to 340B drug discount program Issues related to incentivizing antibiotics Use of medical devices Issues related to AIDS Research and development funding for responding to pandemics (Ebola and Zika) Issues related to expanded access Issues related to FDA user fees and ACA repeal/replace
Issues related to pseudoephedrine Issues related to the regulation of cosmetic products Safe use of OTC products Matters related to American Medical Association Resolution 208(A-16) adopted April 2016
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ANHEUSER-BUSCH COMPANIES, LLC via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2017 · third_quarter · Q3
Issues related to competition policy
ANHEUSER-BUSCH COMPANIES, LLC via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2017 · second_quarter · Q2
Issues related to competition policy
LAWYERS FOR CIVIL JUSTICE via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2017 · second_quarter · Q2
Advocating improvements in the civil justice system including class actions, discovery, evidence, jurisdiction, and pleadings
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAXTER HEALTHCARE CORPORATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2017 · second_quarter · Q2
Healthcare reform In-home dialysis Telemedicine Availability of medical products H.R. 1245 - Affordable and Safe Prescription Drug Importation Act S. 934/H.R. 2430 - FDA Reauthorization Act of 2017
Funding issues for Medicare Part B 340 B drug discount program
Corporate tax issues, including deferral and device tax Tax reform Issues related to the border adjustment tax
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONSUMER HEALTHCARE PRODUCTS ASSOCIATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2017 · second_quarter · Q2
Dietary Supplement ingredient issues
Preserving consumer access to over-the-counter medicines containing pseudoephedrine Rx-to-OTC switch Issues related to monograph reform
Dextromethorphan Legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications H.R. 1271 - DXM Abuse Prevention Act of 2017
JOHNSON & JOHNSON SERVICES, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2017 · second_quarter · Q2
Issues related to 340B drug discount program Issues related to incentivizing antibiotics Use of medical devices Issues related to AIDS Research and development funding for responding to pandemics (Ebola and Zika) Issues related to expanded access Issues related to FDA user fees and ACA repeal/replace
Issues related to pseudoephedrine Issues related to the regulation of cosmetic products Safe use of OTC products Matters related to American Medical Association Resolution 208(A-16) adopted April 2016
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Agency for International Development (USAID)
THE INSTITUTE FOR LEGAL REFORM - U.S. CHAMBER OF COMMERCE via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2017 · second_quarter · Q2
H.R.985 - Fairness in Class Action Litigation and Furthering Asbestos Claim Transparency Act of 2017 H.R. 720/S. 237 - Lawsuit Abuse Reduction Act of 2017 H.R. 1704 ACCESS Act of 2017 (Accessible Care by Curbing Excessive Lawsuits Act of 2017) CFPB arbitration rule
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ANHEUSER-BUSCH COMPANIES, LLC via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2017 · second_quarter · RA
Issues related to competition policy
BAXTER HEALTHCARE CORPORATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2017 · first_quarter · Q1
Corporate tax issues, including deferral and device tax Tax reform Issues related to the border adjustment tax
Funding issues for Medicare Part B 340 B drug discount program
Healthcare reform In-home dialysis Availability of medical products H.R. 1245 - Affordable and Safe Prescription Drug Importation Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONSUMER HEALTHCARE PRODUCTS ASSOCIATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2017 · first_quarter · Q1
Preserving consumer access to over-the-counter medicines containing pseudoephedrine Rx-to-OTC switch Issues related to monograph reform
Dextromethorphan Legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications H.R. 1271 - DXM Abuse Prevention Act of 2017
Dietary Supplement ingredient issues
LAWYERS FOR CIVIL JUSTICE via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2017 · first_quarter · Q1
Advocating improvements in the civil justice system including class actions, discovery, evidence, jurisdiction, and pleadings
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2017 · first_quarter · Q1
Issues related to pseudoephedrine Issues related to the regulation of cosmetic products Safe use of OTC products Matters related to American Medical Association Resolution 208(A-16) adopted April 2016
Issues related to 340B drug discount program Issues related to incentivizing antibiotics Use of medical devices Issues related to AIDS Research and development funding for responding to pandemics (Ebola and Zika) Issues related to AMA resolution 208(A-16) regarding attorney ads on drug side effects Issues related to expanded access
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Agency for International Development (USAID)
UNIVERSITY OF UTAH via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · fourth_quarter · 4T
Issues related to geothermal energy research
Graduate medical education Issues related to provider reimbursement H.R. 5273 - Helping Hospitals Improve Patient Care Act of 2016
Higher education and research funding Energy research funding Funding for precision medicine research Funding for poison control centers
PFIZER INC via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · first_quarter · 1A
Antitrust issues associated with proposed merger between Pfizer and Allergan
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · fourth_quarter · Q4
Issues related to contact lens pricing Issues related to pseudoephedrine Issues related to the regulation of cosmetic products Safe use of OTC products Matters related to American Medical Association Resolution 208(A-16) adopted April 2016
Issues related to drug shortage Issues related to 340B drug discount program Issues related to incentivizing antibiotics Use of medical devices Issues related to AIDS Research and development funding for responding to pandemics (Ebola and Zika) Issues related to AMA resolution 208(A-16) regarding attorney ads on drug side effects Issues related to expanded access
UNIVERSITY OF UTAH via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · fourth_quarter · Q4
Graduate medical education Issues related to provider reimbursement H.R. 5273 - Helping Hospitals Improve Patient Care Act of 2016
Issues related to geothermal energy research
Higher education and research funding Energy research funding Funding for precision medicine research Funding for poison control centers
BAXTER HEALTHCARE CORPORATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · fourth_quarter · Q4
Corporate tax issues, including deferral and device tax Tax reform
Trade Promotion Authority Trans-Pacific Partnership
Funding issues for Medicare Part B 340 B drug discount program
LAWYERS FOR CIVIL JUSTICE via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · fourth_quarter · Q4
Advocating improvements in the civil justice system including class actions, discovery, evidence, jurisdiction and pleadings
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAFE RX via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · fourth_quarter · Q4
Educating policy makers about anti-pilfering technology known as locking prescription vials (LPVs) Issues relating to establishing a pilot program for LPVs Issues relating to DEA's authority to regulate dispensing Schedule II-IV drugs S. 524/H.R. 953 (PL 114-328) Comprehensive Addiction and Recovery Act of 2016 - Title VII, Section 746 Department of Defense Study on preventing the diversion of opiod medications S. 2943/H.R. 4909 (PL 114-198) National Defense Authorization Act for fiscal year 2017 - Title III, Section 301 Evidence based prescription opiod and heroin treatment and interventions demonstration
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
CONSUMER HEALTHCARE PRODUCTS ASSOCIATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · fourth_quarter · Q4
Preserving consumer access to over-the-counter medicines containing pseudoephedrine Rx-to-OTC switch Issues related to monograph reform
Dietary supplement ingredient issues
Dextromethorphan Legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications
JOHNSON & JOHNSON SERVICES, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · third_quarter · 3A
Issues related to contact lens pricing Issues related to pseudoephedrine Issues related to the regulation of cosmetic products Safe use of OTC products S. 524 Comprehensive Addiction and Recovery Act of 2016 H.R. 953 Comprehensive Addiction and Recovery Act of 2015
H.R. 9 - Innovation Act S. 632 - STRONG Patents Act of 2015
Issues related to drug shortage Issues related to 340B drug discount program Issues related to incentivizing antibiotics Use of medical devices Issues related to AIDS Research and development funding for responding to pandemics (Ebola and Zika) Issues related to AMA resolution 208(A-16) regarding attorney ads on drug side effects Issues related to expanded access
UNIVERSITY OF UTAH via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · third_quarter · Q3
Graduate medical education Issues related to provider reimbursement H.R. 5273 - Helping Hospitals Improve Patient Care Act of 2016
Utah genome project Healthcare delivery innovation Telemedicine Precision medicine Cancer research S. 2873/H.R. 5395 - Expanding Capacity for Health Outcomes Act Zika Research S. 2873 & H.R. 5395 - The ECHO Act H.R. 5273 - Helping Hospitals Improve Patient Care Act of 2016
DHS research priorities Funding for cyber security center
BAXTER HEALTHCARE CORPORATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · third_quarter · Q3
Healthcare reform In-home dialysis H.R. 1130/S.598 - The Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 FDA Reform Availability of medical products
Trade Promotion Authority Trans-Pacific Partnership
Funding issues for Medicare Part B 340 B drug discount program
LAWYERS FOR CIVIL JUSTICE via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · third_quarter · Q3
Advocating improvements in the civil justice system including class actions, discovery, evidence, jurisdiction and pleadings
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAFE RX via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · third_quarter · Q3
Educating policy makers about anti-pilfering technology known as locking prescription vials (LPVs) Issues relating to establishing a pilot program for LPVs Issues relating to DEA's authority to regulate dispensing Schedule II-IV drugs S. 524/H.R. 953 - Comprehensive Addiction and Recovery Act of 2016 S. 2943/H.R. 4909 - National Defense Authorization Act for fiscal year 2017
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
CONSUMER HEALTHCARE PRODUCTS ASSOCIATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · third_quarter · Q3
Dextromethorphan Legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications
Preserving consumer access to over-the-counter medicines containing pseudoephedrine Rx-to-OTC switch Issues related to monograph reform S. 524 - Comprehensive Addiction and Recovery Act of 2016
S.709 - Restoring Access to Medication Act H.R.1270 - Restoring Access to Medication Act
ANHEUSER-BUSCH COMPANIES, LLC via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · third_quarter · Q3
Antitrust issues associated with proposed merger between Anheuser-Busch InBev and SABMiller
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · third_quarter · Q3
Issues related to legal reform
Issues related to drug shortage Issues related to 340B drug discount program Issues related to incentivizing antibiotics Use of medical devices Issues related to AIDS Research and development funding for responding to pandemics (Ebola and Zika) Issues related to AMA resolution 208(A-16) regarding attorney ads on drug side effects Issues related to expanded access
Issues related to contact lens pricing Issues related to pseudoephedrine Issues related to the regulation of cosmetic products Safe use of OTC products S. 524 Comprehensive Addiction and Recovery Act of 2016 H.R. 953 Comprehensive Addiction and Recovery Act of 2015
BAXTER HEALTHCARE CORPORATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · second_quarter · Q2
Healthcare reform In-home dialysis H.R. 1130/S.598 - The Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 FDA Reform Availability of medical products
Corporate tax issues, including deferral and device tax Tax reform
Trade Promotion Authority Trans-Pacific Partnership
CONSUMER HEALTHCARE PRODUCTS ASSOCIATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · second_quarter · Q2
Dietary supplement ingredient issues
Preserving consumer access to over-the-counter medicines containing pseudoephedrine Rx-to-OTC switch Issues related to monograph reform S. 524 - Comprehensive Addiction and Recovery Act of 2016
S.709 - Restoring Access to Medication Act H.R.1270 - Restoring Access to Medication Act
ANHEUSER-BUSCH COMPANIES, LLC via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · second_quarter · Q2
Antitrust issues associated with proposed merger between Anheuser-Busch InBev and SABMiller
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INDUSTRY ORGANIZATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · second_quarter · 2T
H.R.9 - Innovation Act S.1137 - PATENT Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF UTAH via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · second_quarter · Q2
Graduate medical education Issues related to provider reimbursement H.R. 5273 - Helping Hospitals Improve Patient Care Act of 2016
Issues related to geothermal energy research
Higher education and research funding Energy research funding Funding to support training of prosecutors Funding for precision medicine research Funding for poison control centers
SAFE RX via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · second_quarter · Q2
Educating policy makers about anti-pilfering technology known as locking prescription vials (LPVs) Issues relating to establishing a pilot program for LPVs Issues relating to DEA's authority to regulate dispensing Schedule II-IV drugs S. 524/H.R. 953 - Comprehensive Addiction and Recovery Act of 2016 S. 2943/H.R. 4909 - National Defense Authorization Act for fiscal year 2017
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
LAWYERS FOR CIVIL JUSTICE via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · second_quarter · Q2
Advocating improvements in the civil justice system including class actions, discovery, evidence, jurisdiction and pleadings
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · second_quarter · Q2
H.R. 9 - Innovation Act S. 632 - STRONG Patents Act of 2015
Issues related to contact lens pricing Issues related to pseudoephedrine Issues related to the regulation of cosmetic products Safe use of OTC products S. 524 Comprehensive Addiction and Recovery Act of 2016 H.R. 953 Comprehensive Addiction and Recovery Act of 2015
Issues related to legal reform
PFIZER INC via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · second_quarter · 2T
Antitrust issues associated with proposed merger between Pfizer and Allergan
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GREYSTONE EB-5 HOLDINGS CORP. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · first_quarter · Q1
EB-5 and related matters S.1501-American Job Creation and Investment Promotion Reform Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF UTAH via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · first_quarter · Q1
Higher Education Act reauthorization
Graduate medical education Issues related to provider reimbursement
Utah genome project Healthcare delivery innovation Telemedicine Precision medicine Cancer research
SYMPLICITY CORPORATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · first_quarter · Q1
Software evaluation and testing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAFE RX via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · first_quarter · Q1
Educating policy makers about anti-pilfering technology known as locking prescription vials (LPVs) Issues relating to establishing a pilot program for LPVs Issues relating to DEA's authority to regulate dispensing Schedule II-IV drugs
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
PFIZER INC via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · first_quarter · Q1
Antitrust issues associated with proposed merger between Pfizer and Allergan
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LAWYERS FOR CIVIL JUSTICE via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · first_quarter · Q1
Advocating improvements in the civil justice system including class actions, discovery, evidence, jurisdiction and pleadings
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAXALTA INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · first_quarter · 1T
Trade Promotion Authority Trans-Pacific Partnership
Reform of 340 B program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONSUMER HEALTHCARE PRODUCTS ASSOCIATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · first_quarter · Q1
Dietary supplement ingredient issues
Dextromethorphan Legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications
Preserving consumer access to over-the-counter medicines containing pseudoephedrine Rx-to-OTC switch Issues related to monograph reform The Microbead-Free Waters Act of 2015 S. 524 - Comprehensive Addiction and Recovery Act of 2016
BIOTECHNOLOGY INDUSTRY ORGANIZATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · first_quarter · Q1
H.R.9 - Innovation Act S.1137 - PATENT Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ANHEUSER-BUSCH COMPANIES, LLC via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · first_quarter · Q1
Antitrust issues associated with proposed merger between Anheuser-Busch InBev and SABMiller
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAXTER HEALTHCARE CORPORATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · first_quarter · Q1
Trade Promotion Authority Trans-Pacific Partnership
Corporate tax issues, including deferral and device tax Tax reform
Healthcare reform In-home dialysis H.R. 1130/S.598 - The Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 FDA Reform Availability of medical products
JOHNSON & JOHNSON SERVICES, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · first_quarter · Q1
Issues related to contact lens pricing Issues related to pseudoephedrine Issues related to the regulation of cosmetic products Safe use of OTC products S. 524 Comprehensive Addiction and Recovery Act of 2016 H.R. 953 Comprehensive Addiction and Recovery Act of 2015
H.R. 9 - Innovation Act S. 632 - STRONG Patents Act of 2015
Issues related to legal reform
SAFE RX via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2016 · first_quarter · RR
Use of lockable prescription vials for controlled substances in Schedules II-IV
ELECTRONIC PAYMENTS COALITION (EPC) via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · fourth_quarter · 4A
Issues related to financial transaction processing fees Issues related to payment card security, including transition to EMV "chip" cards H.R.2995 - Financial Services and General Government Appropriations Act, 2016 S. 1910 - Financial Services and General Government Appropriations Act, 2016 S.754 - Cybersecurity Information Sharing Act of 2015 H.R.2205 - Data Security Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PFIZER INC via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · fourth_quarter · 4A
Antitrust issues associated with proposed merger between Pfizer and Allergan
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONSUMER HEALTHCARE PRODUCTS ASSOCIATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · fourth_quarter · 4A
S.709 - Restoring Access to Medication Act H.R.1270 - Restoring Access to Medication Act
Dextromethorphan Legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications
Preserving consumer access to over-the-counter medicines containing pseudoephedrine Rx-to-OTC switch Issues related to monograph reform The Microbead-Free Waters Act of 2015
BIOTECHNOLOGY INDUSTRY ORGANIZATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · second_quarter · 2A
H.R.9,Innovation Act S.1137, PATENT Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CIM GROUP via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · first_quarter · 1A
EB5 and related matters Comprehensive immigration reform
Filing targets: HOUSE OF REPRESENTATIVES
PFIZER INC via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · fourth_quarter · Q4
Antitrust issues associated with proposed merger between Pfizer and Allergan
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LAWYERS FOR CIVIL JUSTICE via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · fourth_quarter · Q4
Advocating improvements in the civil justice system including class actions, discovery, evidence, jurisdiction and pleadings
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF UTAH via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · fourth_quarter · Q4
Utah genome project Healthcare delivery innovation Telemedicine Precision medicine
Higher Education Act reauthorization
Graduate medical education Issues related to provider reimbursement
SYMPLICITY CORPORATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · fourth_quarter · Q4
Software evaluation and testing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · fourth_quarter · Q4
Issues related to legal reform
Issues related to contact lens pricing Issues related to pseudoephedrine Issues related to the regulation of cosmetic products
Issues related to drug shortage Issues related to 340B drug discount program Issues related to incentivizing antibiotics Use of medical devices Issues related to AIDS
ELECTRONIC PAYMENTS COALITION (EPC) via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · fourth_quarter · Q4
Issues related to financial transaction processing fees Issues related to payment card security, including transition to EMV "chip" cards H.R.2995 - Financial Services and General Government Appropriations Act, 2016 S. 1910 - Financial Services and General Government Appropriations Act, 2016 S.754 - Cybersecurity Information Sharing Act of 2015 H.R.2205 - Data Security Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONSUMER HEALTHCARE PRODUCTS ASSOCIATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · fourth_quarter · Q4
Dextromethorphan Legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications
S.709 - Restoring Access to Medication Act H.R.1270 - Restoring Access to Medication Act
Preserving consumer access to over-the-counter medicines containing pseudoephedrine Rx-to-OTC switch Issues related to monograph reform The Microbead-Free Waters Act of 2015
GREYSTONE EB-5 HOLDINGS CORP. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · fourth_quarter · Q4
EB-5 and related matters S.1501-American Job Creation and Investment Promotion Reform Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR PATIENT VISION CARE SAFETY via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · fourth_quarter · Q4
Fairness to Contact Lens Consumer Act
Fairness to Contact Lens Consumer Act
BIOTECHNOLOGY INDUSTRY ORGANIZATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · fourth_quarter · Q4
H.R.9,Innovation Act S.1137, PATENT Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAXTER HEALTHCARE CORPORATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · fourth_quarter · Q4
Trade Promotion Authority Trans-Pacific Partnership
Corporate tax issues, including deferral and device tax Tax reform
Healthcare reform In-home dialysis H.R. 1130/S.598 - The Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 FDA Reform
BAXALTA INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · fourth_quarter · Q4
Corporate tax issues, including deferral Tax reform
Healthcare reform FDA reform
Reform of 340 B program
ANHEUSER-BUSCH COMPANIES, LLC via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · fourth_quarter · Q4
Antitrust issues associated with proposed merger between Anheuser-Busch InBev and SABMiller
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PFIZER INC via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · fourth_quarter · RA
Antitrust issues associated with proposed merger between Pfizer and Allergan
ANHEUSER-BUSCH COMPANIES, LLC via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · fourth_quarter · RR
Antitrust issues associated with proposed merger between Anheuser-Busch InBev and SABMiller
ELECTRONIC PAYMENTS COALITION (EPC) via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · third_quarter · 3A
Issues related to financial transaction processing fees Issues related to payment card security, including transition to EMV "chip" cards S.Con.Res.11 - An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025. H.Con.Res.27 - Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025. H.R.2995 - Financial Services and General Government Appropriations Act, 2016 S. 1910 - Financial Services and General Government Appropriations Act, 2016 S.754 - Cybersecurity Information Sharing Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INDUSTRY ORGANIZATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · third_quarter · 3A
H.R.9,Innovation Act S.1137, PATENT Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELECTRONIC PAYMENTS COALITION (EPC) via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · third_quarter · Q3
Issues related to financial transaction processing fees Issues related to payment card security, including transition to EMV "chip" cards S.Con.Res.11 - An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025. H.Con.Res.27 - Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025. H.R.2995 - Financial Services and General Government Appropriations Act, 2016 S. 1910 - Financial Services and General Government Appropriations Act, 2016 S.754 - Cybersecurity Information Sharing Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COALITION FOR PATIENT VISION CARE SAFETY via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · third_quarter · Q3
Fairness to Contact Lens Consumer Act
Fairness to Contact Lens Consumer Act
BIOTECHNOLOGY INDUSTRY ORGANIZATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · third_quarter · Q3
H.R.9,Innovation Act S.1137, PATENT Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAXALTA INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · third_quarter · 3A
Trade Promotion Authority Trans-Pacific Partnership
Reform of 340 B program
Corporate tax issues, including deferral Tax reform
WEST VALLEY WATER DISTRICT via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · third_quarter · 3T
Funding from the Environmental Security Technology Certification Program
Clean-up of perchlorate contamination in the Inland Empire
Funding for the Environmental Security Technology Certification Program Issues relating to perchlorate cleanup in the Inland Empire
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
UNIVERSITY OF UTAH via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · third_quarter · Q3
Higher Education Act reauthorization
Higher education and research funding Energy research funding Funding to support training of prosecutors Funding for precision medicine research
Utah genome project Healthcare delivery innovation Telemedicine Precision medicine
SYMPLICITY CORPORATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · third_quarter · Q3
Software evaluation and testing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LAWYERS FOR CIVIL JUSTICE via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · third_quarter · Q3
Advocating improvements in the civil justice system including class actions, discovery, evidence, jurisdiction and pleadings
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
JOHNSON & JOHNSON SERVICES, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · third_quarter · Q3
H.R. 9 - Innovation Act S. 632 - STRONG Patents Act of 2015
Issues related to drug shortage Issues related to 340B drug discount program Issues related to incentivizing antibiotics Use of medical devices Issues related to AIDS
Issues related to legal reform
CONSUMER HEALTHCARE PRODUCTS ASSOCIATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · third_quarter · Q3
Preserving consumer access to over-the-counter medicines containing pseudoephedrine Rx-to-OTC switch
S.709 - Restoring Access to Medication Act H.R.1270 - Restoring Access to Medication Act
Dietary supplement ingredient issues
BAXTER HEALTHCARE CORPORATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · third_quarter · Q3
Funding issues for Medicare Part B 340 B drug discount program
Corporate tax issues, including deferral and device tax Tax reform
Trade Promotion Authority Trans-Pacific Partnership
GREYSTONE EB-5 HOLDINGS CORP. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2015 · third_quarter · Q3
EB-5 and related matters S.1501-American Job Creation and Investment Promotion Reform Act of 2015
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to utilization of HSA and FSA H.R. 394/S. 85 - Restoring Access to Medication Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to utilization of HSA and FSA H.R. 394/S. 85 - Restoring Access to Medication Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Utah genome project Healthcare delivery innovation Telemedicine Precision medicine Cancer research S. 2873/H.R. 5395 - Expanding Capacity for Health Outcomes Act Zika Research S. 2873 & H.R. 5395 - The ECHO Act H.R. 5273 - Helping Hospitals Improve Patient Care Act of 2016
DHS research priorities Funding for cyber security center
Higher Education Act reauthorization
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS)
Issues related to legal reform
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Agency for International Development (USAID), White House Office
Utah genome project Healthcare delivery innovation Telemedicine Precision medicine Cancer research S. 2873/H.R. 5395 - Expanding Capacity for Health Outcomes Act H.R. 5273 - Helping Hospitals Improve Patient Care Act of 2016
DHS research priorities Funding for cyber security center
Higher Education Act reauthorization
Filing targets: Centers For Medicare and Medicaid Services (CMS), Education, Dept of, Energy, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), White House Office
Healthcare reform In-home dialysis H.R. 1130/S.598 - The Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 FDA Reform - 21st Century Cures Act Availability of medical products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S.709 - Restoring Access to Medication Act H.R.1270 - Restoring Access to Medication Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to legal reform
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Agency for International Development (USAID), White House Office
Higher Education Act reauthorization
Issues related to geothermal energy research
Higher education and research funding Energy research funding Funding for precision medicine research Funding for poison control centers
Filing targets: Centers For Medicare and Medicaid Services (CMS), Education, Dept of, Energy, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), White House Office
Corporate tax issues, including deferral and device tax Tax reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Dietary supplement ingredient issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 9 - Innovation Act S. 632 - STRONG Patents Act of 2015
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Agency for International Development (USAID), White House Office
Funding issues for Medicare Part B 340 B drug discount program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Dextromethorphan Legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Utah genome project Healthcare delivery innovation Telemedicine Precision medicine Cancer research S. 2873/H.R. 5395 - Expanding Capacity for Health Outcomes Act
Higher Education Act reauthorization
Filing targets: Centers For Medicare and Medicaid Services (CMS), Education, Dept of, Energy, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), White House Office
Issues related to drug shortage Issues related to 340B drug discount program Issues related to incentivizing antibiotics Use of medical devices Issues related to AIDS Research and development funding for responding to pandemics (Ebola and Zika)
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), White House Office
Higher education and research funding Energy research funding Funding to support training of prosecutors Funding for precision medicine research Funding for poison control centers
Filing targets: Centers For Medicare and Medicaid Services (CMS), Education, Dept of, Energy, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), White House Office
S.709 - Restoring Access to Medication Act H.R.1270 - Restoring Access to Medication Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Funding issues for Medicare Part B 340 B drug discount program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to drug shortage Issues related to 340B drug discount program Issues related to incentivizing antibiotics Use of medical devices Issues related to AIDS
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), White House Office
Dietary supplement ingredient issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Higher education and research funding Energy research funding Funding to support training of prosecutors Funding for precision medicine research
Filing targets: Centers For Medicare and Medicaid Services (CMS), Education, Dept of, Energy, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), White House Office
H.R. 9 - Innovation Act S. 632 - STRONG Patents Act of 2015
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), White House Office
Dietary supplement ingredient issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Funding issues for Medicare Part B 340 B drug discount program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Trade Promotion Authority Trans-Pacific Partnership
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Healthcare reform FDA reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Graduate medical education
Filing targets: Centers For Medicare and Medicaid Services (CMS), Education, Dept of, Energy, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, State, Dept of (DOS), White House Office
Issues related to contact lens pricing Issues related to pseudoephedrine Issues related to the regulation of cosmetic products
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), White House Office
Dextromethorphan Legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Healthcare reform In-home dialysis H.R. 1130/S.598 - The Chronic Kidney Disease Improvement in Research and Treatment Act of 2015 FDA Reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE